<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>The Neuroscience Journal of Shefaye Khatam</title>
<title_fa>مجله علوم اعصاب شفای خاتم</title_fa>
<short_title>Shefaye Khatam</short_title>
<subject>Medical Sciences</subject>
<web_url>http://shefayekhatam.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2322-1887</journal_id_issn>
<journal_id_issn_online>2345-4814</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/shefa</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>fa</language>
<pubdate>
	<type>jalali</type>
	<year>1396</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2017</year>
	<month>4</month>
	<day>1</day>
</pubdate>
<volume>5</volume>
<number>2</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa>P 32: The Role of CB2 Activation in Rats Under Harmaline Toxicity</title_fa>
	<title>P 32: The Role of CB2 Activation in Rats Under Harmaline Toxicity</title>
	<subject_fa>تحقیقات پایه در علوم اعصاب</subject_fa>
	<subject>Basic research in Neuroscience</subject>
	<content_type_fa>پژوهشي</content_type_fa>
	<content_type>Research --- Open Access, CC-BY-NC</content_type>
	<abstract_fa>&lt;table border=&quot;0&quot; cellpadding=&quot;5px&quot; cellspacing=&quot;2&quot; dir=&quot;rtl&quot; id=&quot;table_article&quot; style=&quot;font-family: Tahoma; background-color: rgb(251, 250, 249); break-inside: avoid !important;&quot; width=&quot;100%&quot;&gt;
	&lt;tbody style=&quot;break-inside: avoid !important; font-size: 12px; margin-top: 0px; line-height: 2.2; margin-bottom: 0px; text-align: justify;&quot;&gt;
		&lt;tr style=&quot;break-inside: avoid !important;&quot;&gt;
			&lt;td class=&quot;abstractmed&quot; colspan=&quot;2&quot; style=&quot;break-inside: avoid !important;&quot;&gt;
			&lt;p style=&quot;font-size: 12px; margin-top: 0px; margin-bottom: 0px; text-align: center;&quot;&gt;&lt;span style=&quot;color: rgb(0, 0, 0); font-size: 12px; line-height: 20.8px;&quot;&gt;لطفاً به چکیده انگلیسی مراجعه شود.&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style=&quot;break-inside: avoid !important;&quot;&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;&lt;/p&gt;
</abstract_fa>
	<abstract>&lt;p&gt;&lt;strong&gt;Introduction:&lt;/strong&gt;&amp;nbsp;&lt;em&gt;&amp;beta;&lt;/em&gt;-carbolines&amp;nbsp;are shown to have significant anti-inflammatory effect via the inhibition of some inflammatory mediators including TNF-&amp;alpha; and PGE2. In previous studies Purkinje cell deterioration have been proposed the dominant pathogenesis of harmaline toxicity. WIN55, 212-2 is a non-selective cannabinoid CB&lt;sub&gt;1&lt;/sub&gt; and CB&lt;sub&gt;2&lt;/sub&gt; receptor agonist. Combination of WIN55, 212-2 and AM 251(&lt;a href=&quot;https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=2&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwiI9Mjd3L7SAhXHOBQKHQMvDgEQFggbMAE&amp;url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4234427%2F&amp;usg=AFQjCNEn-48oVBAQ3grSiBP-POS2febBFA&amp;sig2=LZGOocWiPOFBFX78CwvPGw&quot;&gt;CB1-Selective Cannabinoid Receptor blocker&lt;/a&gt;) can give us activation of CB2 receptor. In this study we aim to evaluate the possible protective effect of this combination against harmaline toxicity. &lt;strong&gt;Materials and Methods:&amp;nbsp; &lt;/strong&gt;30 rats (4 weeks aged) were kept in separate cages. They were randomly distributed into 3 groups. 1) Control, 2) harmaline (30 mg/kg according to our previous pilot study) and 3) WIN55, 212-2 (1mg/kg) +AM 251(1mg/kg) as cannabinoid receptor modulation. Agents were injected i.p. Open field test was used for evaluation of rat&amp;rsquo;s behavior including: mobility, Total distance movement (TDM), velocity, rearing and grooming. Also data collected from rotarod test to evaluate balance motor and balance performances and wire grip test (hanging) to asses muscle strength and balance. &lt;strong&gt;Results&lt;/strong&gt;: Harmaline in this dose reliably affect a significant alteration in all body parts as severe tremor in which in the open field test severely decreases all parameters mentioned. On the other hand treatment with WIN55, 212-2 +AM251 increase both mobility (p&lt;0.0027) and total distance movement (p&lt; 0.0001) in contrast to harmaline. No significant differences were found in the velocity and rearing of harmaline group and WIN55, 212-2 +AM251. Also despite severe alteration in muscle strength and balance, there is no significant decrease in rod and hanging in rats treated by WIN1+AM251 compared to harmaline group. &lt;strong&gt;Conclusion:&lt;/strong&gt; These results allow us to propose that treatment by WIN55,212-2 +AM251 in rats under harmaline toxicity have some positive effects on some aspects of movement&amp;nbsp; by activation CB2 receptors but it needs further investigation on selective modulators and supplementary tests.&lt;/p&gt;
</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Hrmalin, CB2, WIN55,212-2, AM251</keyword>
	<start_page>63</start_page>
	<end_page>63</end_page>
	<web_url>http://shefayekhatam.ir/browse.php?a_code=A-10-24-881&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Nona</first_name>
	<middle_name></middle_name>
	<last_name>Sabeti</last_name>
	<suffix></suffix>
	<first_name_fa>Nona</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>Sabeti</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460011906</code>
	<orcid>100319475328460011906</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Student Research Committee, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran</affiliation>
	<affiliation_fa>Student Research Committee, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran</affiliation_fa>
	 </author>


	<author>
	<first_name>Hasan</first_name>
	<middle_name></middle_name>
	<last_name>Abbassian</last_name>
	<suffix></suffix>
	<first_name_fa>Hasan</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>Abbassian</last_name_fa>
	<suffix_fa></suffix_fa>
	<email>habasian@ymail.com</email>
	<code>100319475328460011907</code>
	<orcid>100319475328460011907</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
	<affiliation_fa>Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation_fa>
	 </author>


	<author>
	<first_name>Benjamin</first_name>
	<middle_name></middle_name>
	<last_name>Jason Walley</last_name>
	<suffix></suffix>
	<first_name_fa>Benjamin</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>Jason Walley</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460011908</code>
	<orcid>100319475328460011908</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Pharmacy, School of Chemistry, Food and Nutritional Sciences and Pharmacy, University of Reading, Whiteknights, Reading, Berkshire, RG6 6AP, UK</affiliation>
	<affiliation_fa>Department of Pharmacy, School of Chemistry, Food and Nutritional Sciences and Pharmacy, University of Reading, Whiteknights, Reading, Berkshire, RG6 6AP, UK</affiliation_fa>
	 </author>


	<author>
	<first_name>Mohammad</first_name>
	<middle_name></middle_name>
	<last_name>Shabani</last_name>
	<suffix></suffix>
	<first_name_fa>Mohammad</first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa>Shabani</last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>100319475328460011909</code>
	<orcid>100319475328460011909</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Kerman Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran</affiliation>
	<affiliation_fa>Kerman Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran</affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
